Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Elisa Giovannetti

Cytidine Deaminase Enzymatic Activity Is a Prognostic Biomarker in Gemcitabine/Platinum-Treated Advanced Non-Small-Cell Lung Cancer: A Prospective Validation Study

British Journal of Cancer

Cancer Research

Oncology

2018

English

Glucocorticoid Resistant Pediatric Acute Lymphoblastic Leukemia Samples Display Altered Splicing Profile and Vulnerability to Spliceosome Modulation

English

Multifactorial Resistance to Aminopeptidase Inhibitor Prodrug CHR2863 in Myeloid Leukemia Cells: Down-Regulation of Carboxylesterase 1, Drug Sequestration in Lipid Droplets and Pro-Survival Activation ERK/Akt/mTOR

Oncotarget

Oncology

2015

English

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells With MET Amplification

PLoS ONE

Multidisciplinary

2013

English

New Developments in the Management of Non-Small-Cell Lung Cancer, Focus on Rociletinib: What Went Wrong?

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

On the Pharmacogenetics of Non-Small Cell Lung Cancer Treatment

Expert Opinion on Drug Metabolism and Toxicology

English

Is There a Role for Dacomitinib, a Second-Generation Irreversible Inhibitor of the Epidermal-Growth Factor Receptor Tyrosine Kinase, in Advanced Non-Small Cell Lung Cancer?

Expert Opinion on Pharmacotherapy

Medicine

Pharmacology

2020

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Elisa Giovannetti

Cytidine Deaminase Enzymatic Activity Is a Prognostic Biomarker in Gemcitabine/Platinum-Treated Advanced Non-Small-Cell Lung Cancer: A Prospective Validation Study

Glucocorticoid Resistant Pediatric Acute Lymphoblastic Leukemia Samples Display Altered Splicing Profile and Vulnerability to Spliceosome Modulation

Multifactorial Resistance to Aminopeptidase Inhibitor Prodrug CHR2863 in Myeloid Leukemia Cells: Down-Regulation of Carboxylesterase 1, Drug Sequestration in Lipid Droplets and Pro-Survival Activation ERK/Akt/mTOR

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells With MET Amplification

New Developments in the Management of Non-Small-Cell Lung Cancer, Focus on Rociletinib: What Went Wrong?

On the Pharmacogenetics of Non-Small Cell Lung Cancer Treatment

Is There a Role for Dacomitinib, a Second-Generation Irreversible Inhibitor of the Epidermal-Growth Factor Receptor Tyrosine Kinase, in Advanced Non-Small Cell Lung Cancer?